Research Analysts Offer Predictions for Humacyte Q3 Earnings

Humacyte, Inc. (NASDAQ:HUMA - Free Report) - HC Wainwright issued their Q3 2024 EPS estimates for shares of Humacyte in a note issued to investors on Tuesday, November 5th. HC Wainwright analyst V. Bernardino expects that the company will post earnings of ($0.26) per share for the quarter. HC Wainwright has a "Buy" rating and a $12.00 price target on the stock. The consensus estimate for Humacyte's current full-year earnings is ($1.09) per share. HC Wainwright also issued estimates for Humacyte's Q4 2024 earnings at ($0.26) EPS, FY2024 earnings at ($1.28) EPS, FY2025 earnings at ($0.76) EPS, FY2026 earnings at ($0.17) EPS and FY2027 earnings at $0.24 EPS.

Humacyte (NASDAQ:HUMA - Get Free Report) last announced its quarterly earnings data on Tuesday, August 13th. The company reported ($0.27) earnings per share for the quarter, missing analysts' consensus estimates of ($0.23) by ($0.04).

Several other research firms have also recently weighed in on HUMA. Benchmark reissued a "buy" rating and set a $15.00 price objective on shares of Humacyte in a report on Thursday, October 10th. Piper Sandler set a $6.00 target price on shares of Humacyte and gave the company a "neutral" rating in a research note on Friday, October 18th. Cantor Fitzgerald restated an "overweight" rating and set a $13.00 price target on shares of Humacyte in a research note on Friday, September 20th. BTIG Research restated a "buy" rating and issued a $10.00 price objective on shares of Humacyte in a research note on Friday, October 18th. Finally, EF Hutton Acquisition Co. I raised Humacyte to a "strong-buy" rating in a report on Monday, September 9th. One equities research analyst has rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, Humacyte currently has a consensus rating of "Buy" and an average price target of $11.00.

Humacyte Stock Down 3.1 %

Shares of HUMA stock traded down $0.17 during mid-day trading on Thursday, hitting $5.26. The company's stock had a trading volume of 2,525,306 shares, compared to its average volume of 2,346,292. Humacyte has a 52-week low of $2.08 and a 52-week high of $9.97. The business has a 50-day moving average price of $5.47 and a 200 day moving average price of $6.11. The company has a debt-to-equity ratio of 0.61, a quick ratio of 5.41 and a current ratio of 5.41. The stock has a market cap of $627.79 million, a price-to-earnings ratio of -4.17 and a beta of 1.47.

Institutional Investors Weigh In On Humacyte

Large investors have recently modified their holdings of the business. nVerses Capital LLC purchased a new position in shares of Humacyte during the 2nd quarter valued at about $28,000. Concurrent Investment Advisors LLC acquired a new position in Humacyte in the third quarter valued at approximately $75,000. Principal Financial Group Inc. acquired a new stake in shares of Humacyte during the 2nd quarter worth approximately $83,000. Profund Advisors LLC purchased a new position in shares of Humacyte during the 2nd quarter valued at approximately $97,000. Finally, XTX Topco Ltd acquired a new position in shares of Humacyte in the 2nd quarter valued at $110,000. Hedge funds and other institutional investors own 44.71% of the company's stock.

Insider Transactions at Humacyte

In other Humacyte news, CEO Laura E. Niklason sold 157,704 shares of the company's stock in a transaction on Monday, September 9th. The stock was sold at an average price of $5.42, for a total value of $854,755.68. Following the transaction, the chief executive officer now owns 3,519,558 shares of the company's stock, valued at $19,076,004.36. This represents a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. In related news, Director Brady W. Dougan sold 352,112 shares of the company's stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $6.35, for a total transaction of $2,235,911.20. Following the completion of the sale, the director now directly owns 3,677,262 shares in the company, valued at $23,350,613.70. This represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CEO Laura E. Niklason sold 157,704 shares of the firm's stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $5.42, for a total transaction of $854,755.68. Following the completion of the sale, the chief executive officer now owns 3,519,558 shares in the company, valued at $19,076,004.36. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders sold 1,084,153 shares of company stock worth $6,869,996. 11.20% of the stock is currently owned by insiders.

Humacyte Company Profile

Humacyte, Inc engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.